TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03684837

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamine D supplementation
Description: a vitamine D dose for week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chronic exercise in whole body vibration (WBV)
Description: exercise in WBV during 03 months, e times per week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: chronic exercise in whole body vibration (WBV)
Description: exercise in WBV during 03 months, e times per week
Study: NCT04791657

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical treatment for appendicitis

Intervention type: PROCEDURE
Intervention: Appendectomy
Description: Surgical treatment for appendicitis
Study: NCT00383331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles~B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles~B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles
Study: NCT00130104

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transthecal Metacarpal Block
Study: NCT00804895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTIM, cortivazol injections
Description: ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PROAMP, subcutaneous serum physiological saline
Description: Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: standard prophylactic treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Verapamil
Description: standard prophylactic treatment
Study: NCT03024112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heated humified high-flow nasal cannula Oxygen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy
Study: NCT02951234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IVIG only
Description: All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVIG and Aspirin
Description: All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
Study: NCT00422188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic Acid Injection
Description: Administered via intralipomal injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via intralipomal injection.
Study: NCT01939522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Study: NCT03380507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple therapy group
Description: Refer to arms description
Study: NCT01960426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of drug (Adalimumab/Infliximab)
Description: Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensify treatment with the existing drug
Description: Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
Study: NCT03924648

Intervention type: OTHER
Intervention: Endocan levels
Description: Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.

Intervention type: OTHER
Intervention: Endocan levels
Description: Venous blood sample from the antecubital veins for measuring serum concentration of Endocan. The serum endocan level was measured using a commercially available ELISA kit, which is produced to detect human endocan levels with high sensitivity and specificity (Elabscience Biotechnology Inc., Houston, TX, USA). The endocan measurements were performed in accordance with company's protocol.
Study: NCT01742091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV
Study: NCT03086616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
Description: Nal-IRI will be given directly into the tumor using CED.
Study: NCT01540786

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High resolution urodynamic assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High resolution urodynamic assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High resolution urodynamic assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional urodynamic assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional urodynamic assessment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional urodynamic assessment
Study: NCT03472820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Recommendations
Description: Specific dietary guidelines will be outlined for participants.
Study: NCT01742091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2541546 - IV
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo - IV
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - IV
Description: Administered IV
Study: NCT03472820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Recommendations
Description: Participants are encouraged to average a minimum of 7 hours of sleep per night.
Study: NCT02333669

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT03148964

Intervention type: BIOLOGICAL
Intervention: blood sampling
Description: Blood Sampling at J0, M1, M3, M6, M12, M24 and every 12 months until the end of the study
Study: NCT00484276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
Study: NCT03219801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cells
Description: SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
Study: NCT03669406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autograft fat
Description: autograft fat
Study: NCT01670812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFP+HDMP+Rituximab
Description: This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
Study: NCT03966495

Intervention type: OTHER
Intervention: Sustainability of a research program in risk management
Description: No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)

Intervention type: OTHER
Intervention: Sustainability of a research program in risk management
Description: No intervention will be implemented in the present study.~The investigators will evaluate of the sustainability of a research program in risk management in pluriprofessional primary care offices:~* Qualitatively assessed safety culture and Sustainability of the PRisM RM program in the offices by interviews of professional belonging to the offices.~* Quantitatively assessed safety climate in the offices measured by the Medical Office Survey on Patient Safety Culture (MOSPS) Questionnaire (fill in by the professionals of the offices)
Study: NCT03472820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Recommendations
Description: Participants will be encouraged to exercise a minimum of 30 minutes at least 5 days per week at an intensity of 60-80% of maximum perceived exertion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress Management Recommendations
Description: Participants will utilize the Cleveland Clinic's Stress Free Now application to engage in a variety of guided stress reduction techniques, including meditation and mindful breathing. Recommended frequency is twice daily, preferably morning and evening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PhytoGanix (tropical fruit flavor)
Description: Organic Superfruits \& Greens Powder Drink Mix is a food-based phytonutrient blend. Participants will take 2 servings daily in divided doses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UltraFlora Intensive Care
Description: Probiotic; Participants will take 2 capsules of UltraFlora Intensive Care probiotic daily in divided doses.
Study: NCT04124055

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM)
Description: Saliva and dried blood spot samples are collected. Based on the measured drug concentration the dose can be adjusted
Study: NCT03465384

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comet
Description: The intervention is a behaviorally based and manualized parent training program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comet
Description: The intervention is a behaviorally based and manualized parent training program.
Study: NCT00829127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8075
Description: single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study: NCT00565812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-6010
Description: 200 mg tablets once a day for 2 years
Study: NCT01766037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspiration Therapy (AspireAssist)
Description: Use of the AspireAssist device in aspiration therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Therapy
Description: Lifestyle therapy is a behavioral, diet and physical activity education program
Study: NCT04544644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104+anlotinib
Description: AK 104 is given by intravenous infusion and anlotinib is given by oral.
Study: NCT01268046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol oral capsule
Description: 1 oral capsule (1 mg estradiol) administered daily for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol oral capsule
Description: 1 oral capsule (1 mg estradiol) administered daily for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transderman estrogen patch
Description: transdermal estrogen patch (50 mcg/day) for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transderman estrogen patch
Description: transdermal estrogen patch (50 mcg/day) for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trasdermal placebo patch
Description: transdermal placebo patch with patch change every 84 hr for one month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: trasdermal placebo patch
Description: transdermal placebo patch with patch change every 84 hr for one month
Study: NCT00565812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SD-6010
Description: 50 mg tablets once a day for 2 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once a day for 2 years
Study: NCT01268046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral capsule
Description: placebo oral capsule administered daily for one month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo oral capsule
Description: placebo oral capsule administered daily for one month.
Study: NCT01771991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Sodermix Dismutase in the form of Sodermix (SOD)
Description: Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
Study: NCT04423757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: 125 milligram (mg) BI 1358894 taken orally as three film-coated tablets (1x 25mg and 2x 50mg) once a day in the morning for six weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1358894 taken orally as three film-coated tablets once a day in the morning for six weeks.
Study: NCT01771991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
Study: NCT02859285

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vulvar cream

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol vulvar cream
Study: NCT02967549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: NAVA delivered by the Servo-n ventilator (Maquet)
Study: NCT02129595

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol
Description: resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
Study: NCT04436900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation (PRP)
Description: PRP with ARC with a spot number of 1,200 to 1,500 per eye and spot size 500 micron with a duration of 200 ms.
Study: NCT03010267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R213
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R213
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raloxifene
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecaliferol
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecaliferol
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT00361218

Intervention type: DRUG
Group type: OTHER
Intervention: open-label selective serotonin reuptake inhibitor (SSRI)
Description: Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
Study: NCT03707262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor CD34+ and CD3+ cells
Description: Infusion of GCSF-mobilized, Miltenyi-enriched CD34+ hematopoietic stem/progenitor cells (HSPCs) (≥ 5 million cells/kg) and CD3+ cells (5 million cells/kg) from an HLA-identical sibling living donor, following pre-conditioning regimen of rATG and TLI.
Study: NCT00546507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDS-943 (topical diclofenac sodium 4% spray)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02691364

Intervention type: PROCEDURE
Intervention: Blood withdrawal

Intervention type: PROCEDURE
Intervention: Blood withdrawal
Study: NCT00718523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMG 479 Placebo
Description: Matching placebo administered Day 1 of each 21 day cycle.
Study: NCT01425853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chondroitin/Glucosamine (Droglican)
Description: Experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Active comparator
Study: NCT04110184

Intervention type: OTHER
Intervention: Systemic lupus erythematosus disease activity index (SLEDAI)
Description: The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease

Intervention type: OTHER
Intervention: Systemic lupus erythematosus disease activity index (SLEDAI)
Description: The SLEDAI score ranges between 0 and 105, and scores ≥8 represent active disease
Study: NCT01278420

Intervention type: DEVICE
Group type: OTHER
Intervention: Tecnis MF
Description: 30 subjects will be implanted with the Tecnis MF

Intervention type: DEVICE
Group type: OTHER
Intervention: ReSTOR
Description: 30 subjects will be implanted with ReSTOR
Study: NCT00995696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PhaST IVR Calls
Description: Participants in this condition receive 7 computer automated IVR calls.
Study: NCT00577915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiology/MRI scan
Description: MRI spectroscopy
Study: NCT00217009

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband Ultraviolet B (TL-01UVB) Therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Topical Psoralen plus ultraviolet A (PUVA)
Study: NCT03255304

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health mindest
Description: groups be confronted with health aspects of food items
Study: NCT02967549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: NAVA delivered by the Servo-n ventilator (Maquet)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV
Description: PAV delivered by the Stephanie ventilator (Stephan)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAV
Description: PAV delivered by the Stephanie ventilator (Stephan)
Study: NCT03697161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 (gaboxadol)
Description: OV101 (gaboxadol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OV101 (gaboxadol)
Description: OV101 (gaboxadol)
Study: NCT00126191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
Study: NCT00083551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as \< 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20